

# Margo J H Van Campenhout

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7401022/publications.pdf>

Version: 2024-02-01

16  
papers

450  
citations

706676

14  
h-index

993246

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

757  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2021, 72, 202-211.	2.9	41
2	Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 314-320.	1.9	19
3	Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 610-619.	1.0	21
4	Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 448-456.	1.9	20
5	Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1156-1163.	1.0	17
6	Relationship between hepatitis B core-related antigen levels and sustained <sc>HB</sc>eAg seroconversion in patients treated with nucleo(s)tide analogues. <i>Journal of Viral Hepatitis</i> , 2019, 26, 828-834.	1.0	18
7	Diagnostic and analytical performance of the hepatitis B core related antigen immunoassay in hepatitis B patients. <i>Journal of Clinical Virology</i> , 2019, 114, 1-5.	1.6	13
8	Machine-learning based patient classification using Hepatitis B virus full-length genome quasispecies from Asian and European cohorts. <i>Scientific Reports</i> , 2019, 9, 18892.	1.6	21
9	Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for <sc>HB</sc>eAg-positive chronic hepatitis B infection: <sc>ARES</sc> long-term follow-up. <i>Journal of Viral Hepatitis</i> , 2019, 26, 109-117.	1.0	20
10	Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. <i>Hepatology</i> , 2018, 68, 839-847.	3.6	72
11	Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF). <i>Antiviral Research</i> , 2016, 132, 70-75.	1.9	18
12	Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients. <i>Clinical Microbiology and Infection</i> , 2016, 22, 571.e5-571.e9.	2.8	22
13	CMV Primary Infection Is Associated With Donor-Specific T Cell Hyporesponsiveness and Fewer Late Acute Rejections After Liver Transplantation. <i>American Journal of Transplantation</i> , 2015, 15, 2431-2442.	2.6	25
14	How to achieve immune control in chronic hepatitis B?. <i>Hepatology International</i> , 2015, 9, 9-16.	1.9	10
15	Bachmann's Bundle. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 1041-1046.	2.1	71
16	The best way to prevent cytomegalovirus infection after liver transplantation: the debate goes on. <i>Transplant International</i> , 2013, 26, 590-591.	0.8	3